3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Benchmark H+,K+-ATPase Inhibitor for Gastric Acid Secretion and Antiulcer Research

Principle Overview: Mechanism and Rationale for Use

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is a highly selective small-molecule H+,K+-ATPase inhibitor (SKU: A2845), supplied by APExBIO. With an IC₅₀ of 5.8 μM against H+,K+-ATPase and a sub-micromolar potency (IC₅₀ = 0.16 μM) for histamine-induced gastric acid secretion inhibition, this compound has emerged as a leading gastric acid secretion inhibitor for modern research. Its dual action—antisecretory and antiulcer—enables robust modeling of the proton pump inhibition pathway and downstream effects in gastrointestinal and systemic disease models.

By targeting the gastric H+,K+-ATPase, this agent effectively blocks the final step of acid production, providing a reliable tool for dissecting the H+,K+-ATPase signaling pathway in both gastric acid-related disorders and conditions where acid modulation is a variable, such as peptic ulcer disease models and neuroinflammation studies.

Step-by-Step Experimental Workflow and Protocol Enhancements

1. Compound Preparation

• Solubility: The compound is insoluble in water and ethanol but dissolves readily in DMSO (≥17.27 mg/mL). Prepare concentrated stocks (e.g., 10–20 mM in DMSO) for aliquoting and minimize freeze-thaw cycles.
• Storage: Store lyophilized powder at -20°C. Avoid long-term storage of solutions; prepare fresh working dilutions prior to each experiment to maintain integrity and potency.

2. In Vitro Gastric Acid Secretion Assays

• Cell Lines: Use parietal cell-enriched preparations or immortalized gastric cell lines (e.g., HGT-1) for direct assessment of acid secretion.
• Assay Design: Stimulate acid secretion with histamine (or carbachol) and introduce serial dilutions of the compound. Monitor pH changes or use fluorometric acid secretion indicators.
• Quantification: Calculate inhibition curves and IC₅₀ values. Expect robust inhibition at sub-micromolar concentrations for histamine-induced acid secretion, consistent with published data (see validation).

3. In Vivo Models: Peptic Ulcer and Gastric Acid-Related Disorders

• Dosing: Dissolve in DMSO and dilute with compatible vehicles (e.g., PEG400, saline with 10% DMSO), keeping final DMSO concentrations ≤1% in vivo.
• Models: Employ standardized peptic ulcer models (e.g., indomethacin-induced, ethanol-induced, or pylorus ligation models) to assess antiulcer activity. Quantify ulcer index, histopathology, and gastric pH.
• Comparative Controls: Include positive controls (e.g., omeprazole, ic omeprazole) for benchmarking efficacy, referencing proven IC₅₀ values and antiulcer profiles (see mechanistic review).

4. Integration with Neuroinflammation and Gut–Liver–Brain Axis Research

• Cross-Disciplinary Models: Combine gastric acid modulation with hepatic encephalopathy, gut microbiota, or neuroinflammation studies. For example, modulating gastric acidity can impact gut microbiome and, by extension, neuroinflammatory outcomes—as seen in the reference study by Kong et al. (2025) evaluating the gut–liver–brain axis.
• Readouts: Use PET imaging (e.g., [18F]PBR146), cytokine profiling, and behavioral assays to link antiulcer agent intervention with systemic and neurological outcomes.

Advanced Applications and Comparative Advantages

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide offers several competitive advantages for gastric acid secretion research and antiulcer activity study workflows:

• High Purity and Reproducibility: Supplied at ~98% purity (HPLC/NMR-verified), guaranteeing consistent results across experiments.
• Superior Potency: Demonstrated sub-micromolar efficacy for histamine-induced gastric acid inhibition, outperforming some legacy proton pump inhibitors in select models (see comparative analysis).
• Robust Handling: The compound’s stability at -20°C and high DMSO solubility enable flexible dosing regimens and multi-assay compatibility.
• Translational Versatility: Its defined inhibition profile allows precise modeling in both acute and chronic settings, supporting studies from basic acid secretion to complex disease models involving the gut–liver–brain axis (complementary review).

For a detailed protocol and troubleshooting best practices, the article Solving Lab Challenges with 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide directly complements this guide, offering scenario-driven strategies for optimizing cytotoxicity and secretion assays.

Troubleshooting and Optimization Tips

• Incomplete Inhibition Curves: If IC₅₀ values appear inconsistent with published data (see reproducibility analysis), verify compound solubilization and assay pH. Residual undissolved material or pH drift can reduce apparent potency.
• Cellular Toxicity: At higher concentrations, DMSO or the compound itself may induce off-target effects. Use minimal DMSO (<1%) and titrate dosages carefully in cell-based assays. Cross-reference with cytotoxicity data for your cell line.
• Batch-to-Batch Variability: Always verify receipt of the latest COA and batch purity from APExBIO. Store under desiccated, light-protected conditions at -20°C to prevent degradation.
• In Vivo Delivery: If precipitation occurs after dilution, use co-solvents such as PEG400 or Tween-80. Warm gently to ensure complete dissolution, but do not exceed 37°C to avoid decomposition.
• Gastric pH Measurements: For animal models, calibrate pH probes before each experiment and standardize sampling times to reduce variability in acid output measurements.

The article Optimizing Gastric Acid Secretion Research with a Potent H+,K+-ATPase Inhibitor extends these troubleshooting recommendations with workflow diagrams and protocol enhancements tailored for high-throughput research environments.

Future Outlook: Expanding the Scope of H+,K+-ATPase Inhibition in Translational Research

With growing recognition of the gastric proton pump’s role in extra-gastric conditions—ranging from systemic inflammation to neuroinflammation—the translational impact of precise gastric acid secretion inhibitors continues to expand. The study by Kong et al. (2025) highlights the utility of gut-targeted interventions in models of hepatic encephalopathy, revealing how gastric and microbiome modulation can influence brain inflammation and function. Incorporating agents like 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide into such workflows enables researchers to disentangle the complex links between acid regulation, microbiota, and systemic outcomes.

Looking forward, integration with advanced imaging (e.g., PET, MRI), multi-omics (metabolomics, microbiomics), and behavioral analytics will further enhance the power of antiulcer agents for research. As the field moves toward more personalized and mechanistically informed models of gastric acid-related disorders, the demand for highly pure, well-characterized inhibitors—like those from APExBIO—will remain paramount.

Conclusion

For investigators seeking rigorous, reproducible, and translationally relevant results in gastric acid secretion and antiulcer research, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide stands out as a best-in-class tool. Its powerful H+,K+-ATPase inhibition, high purity, and proven track record—supported by APExBIO’s quality assurance—make it an essential component of modern experimental workflows. By leveraging protocol optimizations and troubleshooting strategies highlighted above, researchers can maximize signal fidelity, minimize artifacts, and accelerate discovery in both traditional and emerging models of gastric acid and systemic disease.